A. Middel

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial

A. Wensing, J. Borghans, C. Richter, 2015, PloS one.

A highly virulent variant of HIV-1 circulating in the Netherlands

Michael J. Rausch, H. Jessen, A. Trkola, 2022, Science.

The antiretroviral CCR5-inhibitor maraviroc effectively reverses HIV latency by phosphorylation of Nf-kappa B

A. Wensing, S. Lewin, J. Borghans, 2018 .

The Dutch Working Party on Antibiotic Policy (SWAB) guideline for the approach to suspected antibiotic allergy.

J. Schoones, L. Bode, A. Sprikkelman, 2023, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Clinical and immunologic effects of maraviroc in progressive multifocal leukoencephalopathy

C. Frijns, R. Schuurman, K. Tesselaar, 2015, Neurology.